120 related articles for article (PubMed ID: 38328844)
1. SOLUBLE CD150 ISOFORM LEVEL IN PLASMA OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.
Gordiienko I; Shcherbina V; Shlapatska L
Exp Oncol; 2024 Feb; 45(4):457-462. PubMed ID: 38328844
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors.
Shcherbina V; Gordiienko I; Shlapatska L; Ivanivska T; Sidorenko S
Exp Oncol; 2020 Mar; 42(1):16-24. PubMed ID: 32231196
[TBL] [Abstract][Full Text] [Related]
3. The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.
Gordiienko I; Shlapatska L; Kholodniuk V; Sklyarenko L; Gluzman DF; Clark EA; Sidorenko SP
PLoS One; 2017; 12(10):e0185940. PubMed ID: 28982149
[TBL] [Abstract][Full Text] [Related]
4. CD150 and CD180 are negative regulators of IL-10 expression and secretion in chronic lymphocytic leukemia B cells.
Shcherbina V; Gordiienko I; Shlapatska L; Gluzman D; Sidorenko S
Neoplasma; 2021 Jul; 68(4):760-769. PubMed ID: 33904315
[TBL] [Abstract][Full Text] [Related]
5. CD150 and CD180 are involved in regulation of transcription factors expression in chronic lymphocytic leukemia cells.
Gordiienko I; Shlapatska L; Kholodniuk VM; Kovalevska L; Ivanivskaya TS; Sidorenko SP
Exp Oncol; 2017 Dec; 39(4):291-298. PubMed ID: 29284783
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of CD150/SLAMF1 in normal and malignant B cells on the different stages of maturation.
Gordiienko IM; Shlapatska LM; Kovalevska LM; Sidorenko SP
Exp Oncol; 2016 Jun; 38(2):101-7. PubMed ID: 27356578
[TBL] [Abstract][Full Text] [Related]
7. The role of CD150-SH2D1A association in CD150 signaling in Hodgkin's lymphoma cell lines.
Yurchenko MY; Kashuba EV; Shlapatska LM; Sivkovich SA; Sidorenko SP
Exp Oncol; 2005 Mar; 27(1):24-30. PubMed ID: 15812353
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD150 in tumors of the central nervous system: identification of a novel isoform.
Romanets-Korbut O; Najakshin AM; Yurchenko M; Malysheva TA; Kovalevska L; Shlapatska LM; Zozulya YA; Taranin AV; Horvat B; Sidorenko SP
PLoS One; 2015; 10(2):e0118302. PubMed ID: 25710480
[TBL] [Abstract][Full Text] [Related]
9. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
[TBL] [Abstract][Full Text] [Related]
10. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia.
Alfarano A; Indraccolo S; Circosta P; Minuzzo S; Vallario A; Zamarchi R; Fregonese A; Calderazzo F; Faldella A; Aragno M; Camaschella C; Amadori A; Caligaris-Cappio F
Blood; 1999 Apr; 93(7):2327-35. PubMed ID: 10090943
[TBL] [Abstract][Full Text] [Related]
11. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
[TBL] [Abstract][Full Text] [Related]
12. SLAMF1/CD150 expression and topology in prostate and breast cancer cell lines.
Gordiienko IM; Lykhova OO; Shcherbina VM; Shlapatska LM
Exp Oncol; 2021 Dec; 43(4):312-316. PubMed ID: 34967540
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion.
Francia di Celle P; Mariani S; Riera L; Stacchini A; Reato G; Foa R
Blood; 1996 May; 87(10):4382-9. PubMed ID: 8639799
[TBL] [Abstract][Full Text] [Related]
14. KLKB1 mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia.
Adamopoulos PG; Kontos CK; Papageorgiou SG; Pappa V; Scorilas A
Clin Biochem; 2015 Sep; 48(13-14):849-54. PubMed ID: 25891023
[TBL] [Abstract][Full Text] [Related]
15. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.
Bologna C; Buonincontri R; Serra S; Vaisitti T; Audrito V; Brusa D; Pagnani A; Coscia M; D'Arena G; Mereu E; Piva R; Furman RR; Rossi D; Gaidano G; Terhorst C; Deaglio S
J Clin Invest; 2016 Jan; 126(1):181-94. PubMed ID: 26619119
[TBL] [Abstract][Full Text] [Related]
16. Predominantly post-transcriptional regulation of activation molecules in chronic lymphocytic leukemia: the case of transferrin receptors.
Chiotoglou I; Smilevska T; Samara M; Likousi S; Belessi C; Athanasiadou I; Stavroyianni N; Samara S; Laoutaris N; Vamvakopoulos N; Anagnostopoulos A; Fassas A; Stamatopoulos K; Kollia P
Blood Cells Mol Dis; 2008; 41(2):203-9. PubMed ID: 18621559
[TBL] [Abstract][Full Text] [Related]
17. The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL).
Giannopoulos K; Schmitt M; Kowal M; Własiuk P; Bojarska-Junak A; Roliński J; Dmoszyńska A
Leuk Res; 2008 Dec; 32(12):1815-9. PubMed ID: 18499249
[TBL] [Abstract][Full Text] [Related]
18. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
Baskar S; Kwong KY; Hofer T; Levy JM; Kennedy MG; Lee E; Staudt LM; Wilson WH; Wiestner A; Rader C
Clin Cancer Res; 2008 Jan; 14(2):396-404. PubMed ID: 18223214
[TBL] [Abstract][Full Text] [Related]
19. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.
Grywalska E; Bartkowiak-Emeryk M; Pasiarski M; Olszewska-Bożek K; Mielnik M; Podgajna M; Pieczykolan M; Hymos A; Fitas E; Surdacka A; Góźdź S; Roliński J
Adv Clin Exp Med; 2018 Jul; 27(7):987-999. PubMed ID: 29893517
[TBL] [Abstract][Full Text] [Related]
20. SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?
Gordiienko I; Shlapatska L; Kovalevska L; Sidorenko SP
Clin Immunol; 2019 Jul; 204():14-22. PubMed ID: 30616923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
